JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2016. Vol. 61. No. 6. P. 57-63
RADIATION THERAPY
S.S. Gordeyev, V.A. Ivanov, A.O. Rasulov, Yu.A. Barsukov, S.I. Tkachev, Yu.E. Surayeva, M.V. Chernykh, D.V. Kuzmichev, E.N. Kozak, A.G. Malikhov, J.M. Madyarov
Chemoradiotherapy in Complicated Locally Advanced or Recurrent Rectal Cancer Treatment
N.N. Blokhin Russian Cancer Research Center of RAMS, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: To investigate the toxicity and feasibility of chemoradiotherapy in patients with complicated locally advanced or recurrent rectal cancer.
Material and methods: Patients who received chemoradiotherapy during 2005–2015 for locally advanced or recurrent rectal cancer with fistulas and/or peritumoral abscesses were included in a retrospective analysis. The control group consisted of patients with uncomplicated мsub>4NxM0 rectal cancer. Endpoints included chemoradiotherapy toxicity, R0 resections rate, postoperative morbidity, pathologic complete response rate.
Results: Grade 3-4 toxicity was recorded in 3 (14.3 %) patients in both groups (study group G4 in 1 patient and G3 in 2 patients, control group G3 in 3 patients, p = 0.267). No difference in the incidence of complications of chemoradiotherapy between groups were observed (p = 0,267). Postoperative complications Grade IIIb in the study group occurred in 1 patient (5.5 %), and in 1 patient in the control group (5.5 %). Overall morbidity was similar in both groups (p = 0.293). R0 resection was intended in 18 patients in both groups and performed in 16 (88.8 %) patients in the study group and in 18 (100 %) in control group. pCR was observed in 3 patients in the study group (17.6 %) and in 1 patient (5,2 %) in control group, p = 0,137.
Conclusion: chemoradiotherapy in patients with complicated locally advanced cancer does not lead to a significant increase in toxicity, allowing R0 resection to be performed to the majority of patients after treatment without increase in morbidity.
Key words: rectal cancer, complicated, fistula, chemoradiotherapy, toxicity
REFERENCES
- Glimelius B., Tiret E., Cervantes A. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013. Vol. 24 Suppl 6. P. 81-88.
- Vestermark L.W., Jensen H.A., Pfeiffer P. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol. 2012. Vol. 51. No. 3. P. 311-317.
- Sato H., Koide Y., Shiota M. et al. Outcomes of preoperative chemoradiotherapy for rectal cancer with invasion to the adjacent organs. Gan To Kagaku Ryoho. 2013. Vol. 40. No. 12. P. 1968-1970.
- Pfeiffer P. High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial. Acta Oncol. 2005. Vol. 44. No. 3. P. 224- 229.
- Kennecke H., Berry S., Wong R. et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur. J. Cancer. 2012. Vol. 48. No. 1. P. 37-45.
- Zhan T., Wang L., Li M. et al. A multidisciplinary clinical treatment of locally advanced rectal cancer complicated with rectovesical fistula: a case report. J. Med. Case Rep. 2012. Vol. 6. P. 369-382.
- Kitahara T., Uemura M., Haraguchi N. et al. Successful treatment of rectal cancer with perineal invasion: Three case reports. Mol. Clin. Oncol. 2014. Vol. 2. No. 4. P. 497-500.
- Murata A., Takatsuka S., Shinkawa H. et al. A case report of metastatic anal fistula cancer treated with neoadjuvant chemotherapy. Gan To Kagaku Ryoho. 2014. Vol. 41. No. 12. P. 1869-1871.
- Nushijima Y., Nakano K., Sugimoto K. et al. A case of primary carcinoma associated with anal fistula. Gan To Kagaku Ryoho. 2014. Vol. 41. No. 12. P. 1872-1874.
- Benjelloun E.B., Aitalalim S., Chbani L. et al. Rectosigmoid adenocarcinoma revealed by metastatic anal fistula. The visible part of the iceberg: a report of two cases with literature review. World J. Surg. Oncol. 2012. Vol. 10. P. 209.
For citation: Gordeyev SS, Ivanov VA, Rasulov AO, Barsukov YuA, Tkachev SI, Surayeva YuE, Chernykh MV, Kuzmichev DV, Kozak EN, Malikhov AG, Madyarov JM. Chemoradiotherapy in Complicated Locally Advanced or Recurrent Rectal Cancer Treatment. Medical Radiology and Radiation Safety. 2016;61(6):57-63. Russian.
PDF (RUS) Full-text article (in Russian)